Pfizer Seeks New Homes For Assets Orphaned By R&D Reorg
New head of out-licensing takes on prospects cast off in Pfizer’s recent exit from non-“high priority” therapeutic areas.
New head of out-licensing takes on prospects cast off in Pfizer’s recent exit from non-“high priority” therapeutic areas.